AbbVie (ABBV) Total Debt (2012 - 2026)

AbbVie has disclosed Total Debt across 15 years of filings, most recently posting $64.5 billion for Q1 2026.

• In Q1 2026, Total Debt fell 5.51% year-over-year to $64.5 billion; the TTM figure through Mar 2026 stood at $64.5 billion (down 5.51% YoY), while the FY2025 annual figure was $61.4 billion, down 8.5% from the prior year.
• Total Debt rose to $64.5 billion in Q1 2026, from $61.4 billion in the prior quarter.
• Over the last five years, Total Debt for ABBV reached as high as $72.9 billion in Q2 2022 and fell as low as $55.8 billion in Q2 2023.
• The 5-year median for Total Debt is $63.8 billion (2024), against an average of $64.4 billion.
• Annual changes were most pronounced in 2022 — Total Debt retreated 25.71% — and 2024, when it advanced 26.56%.
• A 5-year view of Total Debt shows it stood at $63.3 billion in 2022, then dropped by 6.14% to $59.4 billion in 2023, then gained by 13.07% to $67.1 billion in 2024, then decreased by 8.5% to $61.4 billion in 2025, then gained by 5.03% to $64.5 billion in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $64.5 billion, $61.4 billion, and $65.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.